Business Description

Athenex Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
2MT0.GermanyATNX.USA IPO Date
2017-06-14Description
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.74 | |||||
Equity-to-Asset | -0.03 | |||||
Debt-to-Equity | -6.51 | |||||
Debt-to-EBITDA | -0.59 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -7.57 | |||||
Beneish M-Score | -2.67 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.8 | |||||
3-Year EBITDA Growth Rate | 29.4 | |||||
3-Year EPS without NRI Growth Rate | 23.3 | |||||
3-Year FCF Growth Rate | 26.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 4.01 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.49 | |||||
9-Day RSI | 28.26 | |||||
14-Day RSI | 28.45 | |||||
6-1 Month Momentum % | -50 | |||||
12-1 Month Momentum % | -85.34 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.09 | |||||
Quick Ratio | 0.72 | |||||
Cash Ratio | 0.27 | |||||
Days Inventory | 178.12 | |||||
Days Sales Outstanding | 103.77 | |||||
Days Payable | 104.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.4 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 25.94 | |||||
Operating Margin % | -68.52 | |||||
Net Margin % | -100.02 | |||||
ROE % | -433.13 | |||||
ROA % | -44.63 | |||||
ROIC % | -47.78 | |||||
ROC (Joel Greenblatt) % | -170.29 | |||||
ROCE % | -53.27 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.08 | |||||
EV-to-EBIT | -0.31 | |||||
EV-to-EBITDA | -0.32 | |||||
EV-to-Revenue | 0.22 | |||||
EV-to-Forward-Revenue | 1.46 | |||||
EV-to-FCF | -0.3 | |||||
Earnings Yield (Greenblatt) % | -322.58 |
How Athenex Inc (ATNX) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATNX
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Athenex Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 103.403 | ||
EPS (TTM) ($) | -15.88 | ||
Beta | 1.79 | ||
Volatility % | 82.17 | ||
14-Day RSI | 28.45 | ||
14-Day ATR ($) | 0.256249 | ||
20-Day SMA ($) | 1.969 | ||
12-1 Month Momentum % | -85.34 | ||
52-Week Range ($) | 0.98 - 23.8 | ||
Shares Outstanding (Mil) | 8.66 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Athenex Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |
Athenex Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Athenex Inc Frequently Asked Questions
What is Athenex Inc(ATNX)'s stock price today?
The current price of ATNX is $1.22. The 52 week high of ATNX is $23.80 and 52 week low is $0.98.
When is next earnings date of Athenex Inc(ATNX)?
The next earnings date of Athenex Inc(ATNX) is 2023-05-10 Est..
Does Athenex Inc(ATNX) pay dividends? If so, how much?
Athenex Inc(ATNX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |